Article Information
History
- March 13, 2022.
Article Versions
- Version 1 (August 28, 2021 - 11:06).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Lise Jamieson1,2,
- Sydney Rosen1,3,
- Bevis Phiri4,
- Anna Grimsrud5,
- Muya Mwansa6,
- Hilda Shakwelele4,
- Prudence Haimbe4,
- Mpande M Mwenechanya7,
- Priscilla Lumano-Mulenga6,
- Innocent Chimboma6 and
- Brooke E Nichols1,2,3,*
- 1Health Economics and Epidemiology Research Office (HE2RO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 2Department of Medical Microbiology, Amsterdam University Medical Centre, Amsterdam, the Netherlands
- 3Department of Global Health, Boston University School of Public Health, Boston, MA, USA
- 4Clinton Health Access Initiative, Lusaka, Zambia
- 5International AIDS Society, Cape Town, South Africa
- 6Ministry of Health, Lusaka, Zambia
- 7The Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
- ↵*Corresponding author: Brooke Nichols (brooken{at}bu.edu); Department of Global Health, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, USA.Tel:+1 857-544-7250
Posted March 13, 2022.
How soon should patients be eligible for differentiated service delivery models for antiretroviral treatment? Evidence from Zambia
